Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) posted its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), FiscalAI reports. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million.

Perspective Therapeutics Stock Performance

NYSEAMERICAN:CATX traded up $0.02 during trading hours on Monday, hitting $0.86. The company’s stock had a trading volume of 2,930,748 shares, compared to its average volume of 2,354,898. Perspective Therapeutics has a twelve month low of $0.78 and a twelve month high of $6.16. The stock has a fifty day simple moving average of $2.34 and a 200-day simple moving average of $3.49.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CATX. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Bank of America cut their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Piper Sandler reduced their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, September 15th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.